Author:
Wang Chunyan,Li Wentao,Drabek Dubravka,Okba Nisreen M.A.,van Haperen Rien,Osterhaus Albert D.M.E.,van Kuppeveld Frank J.M.,Haagmans Bart L.,Grosveld Frank,Bosch Berend-Jan
Abstract
AbstractThe emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV). This cross-neutralizing antibody targets a communal epitope on these viruses and offers potential for prevention and treatment of COVID-19.
Publisher
Cold Spring Harbor Laboratory
Reference24 articles.
1. Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 1–4 (2020).
2. World Health Organization. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200310-sitrep-50-covid-19.pdf?sfvrsn=55e904fb_2.
3. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. (2020).
4. Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses
5. Antibody-mediated protection against Ebola virus;Nat. Immunol.,2018
Cited by
54 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献